Recommended
November 25, 2025
2025 Recap: Top 10 Company Acquisitions in Ophthalmology
The ophthalmology industry in 2025 continued to evolve through strategic acquisitions and partnerships, strengthening innovation pipelines across gene therapy, diagnostics, surgical technology, and digital eye care.
Breaking News
FDA Approves Amneal Pharmaceuticals’ Cyclosporine Ophthalmic Emulsion 0.05%
Dec 04, 2025
The U.S. Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, a generic version of Restasis, which is a registered trademark of Allergan, an AbbVie company.
Celltrion Receives Health Canada Approval for Eydenzelt
Nov 28, 2025
Celltrion, Inc. has announced that Health Canada has approved Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg), for all indications currently approved for Eylea. Eydenzelt will be available in both vial and pre filled syringe formats.
FDA Approves Glaukos' Epioxa: First Incision-Free Corneal Cross-Linking Therapy for Keratoconus
Oct 21, 2025
The U.S. Food and Drug Administration (FDA) has approved Glaukos’ New Drug Application (NDA) for Epioxa HD/Epioxa, marking a breakthrough in the treatment of keratoconus.
.jpg)
Industry News
ViaLase Initiates First U.S. IDE Trial Patient Treatment for Incision-Free Glaucoma Laser Procedure
Dec 04, 2025
ViaLase has announced the treatment of the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial.
European Regulators Approve Pre-Filled Syringe Version of Byooviz, Lucentis Biosimilar
Dec 03, 2025
Samsung Bioepis has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its pre-filled syringe (PFS) formulation of Byooviz, a biosimilar referencing Lucentis (ranibizumab).
Lotus Submits NDA for Presbyopia Treatment VIZZ in South Korea Under LENZ Partnership
Dec 03, 2025
Lotus Pharmaceutical and LENZ Therapeutics have announced the submission of a New Drug Application (NDA) to South Korea’s Ministry of Food and Drug Safety (MFDS) for the review and potential approval of VIZZ.
Ophthalmic Research News
Dual Mechanisms Behind Rapid Eye Dominance Plasticity Discovered in Adult Brain
Dec 01, 2025
A new study published in Communications Biology has uncovered two distinct yet interconnected mechanisms responsible for ocular dominance plasticity in the adult brain.
Virtual Retina Model Offers Breakthrough Insights for Vision Loss Treatments
Dec 01, 2025
New research from the University of Surrey introduces a pioneering computer model that simulates how the retina forms and regenerates, an innovation that could pave the way for novel treatments for vision loss.
Access to Ophthalmologists in the U.S. Has Improved Over the Last Decade, Study Finds
Nov 28, 2025
A recent research letter published in JAMA Ophthalmology reveals that access to ophthalmologists in the United States has improved between 2014 and 2024.
Ophthalmic Blog
2025 Recap: Top 10 Breakthroughs in Ophthalmology Research
Dec 01, 2025
Ophthalmology research in 2025 was defined by significant progress in regenerative medicine, drug delivery innovation, gene therapy, and vision restoration technologies.
2025 Recap: Top 10 Company Acquisitions in Ophthalmology
Nov 25, 2025
The ophthalmology industry in 2025 continued to evolve through strategic acquisitions and partnerships, strengthening innovation pipelines across gene therapy, diagnostics, surgical technology, and digital eye care.
AI in Ophthalmology: Top Artificial Intelligence Tools Transforming Eye Health
Mar 07, 2025
The AI in ophthalmology sector is evolving rapidly, introducing Artificial Intelligence tools in ophthalmology that enhance diagnostic accuracy, efficiency, and accessibility.
Ophthalmology Breaking News Subscribe